# To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Source: https://onco.cc/trials/nct06344052/  
OnCo record `nct06344052` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Vismodegib in basal cell carcinoma, run by Stamford Pharmaceuticals, Inc., now recruiting.

## Summary

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma is a phase 2 interventional study registered as NCT06344052 by Stamford Pharmaceuticals, Inc., with 80 participants planned, started 2024-04-09 and due to reach its primary completion in 2026-09-30. Interventions recorded: SP-002, Vismodegib. Conditions listed: Basal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06344052
- Phase: 2
- Setting: A Phase 2 Study to Assess the Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
- Sponsor: Stamford Pharmaceuticals, Inc.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06344052: https://clinicaltrials.gov/study/NCT06344052

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/)
- drugs: [Vismodegib](https://onco.cc/drugs/vismodegib/)

---
JSON: https://onco.cc/api/v1/entities/nct06344052.json